Liquid biopsies for management of pancreatic cancer

Samandari, Mohamadmahdi; Juliá, María Gil; Rice, Alistair; Chronopoulos, Antonios; Hernández, Armando E. del Río

doi:10.1016/j.trsl.2018.07.008

Cited by 58 publications

(51 citation statements)

References 245 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the clinical setting, liquid biopsy has been very popular in recent years because it may complement conventional diagnostic methods. The rationale for liquid biopsy is that tumours can release various forms of substances into body fluids, providing us with an opportunity to detect tumours [64].…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis of the diagnostic performance of circulating microRNAs for pancreatic cancer

Peng

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Pancreatic cancer (PC) is characterized by high malignancy and a poor prognosis. The detection of circulating microRNAs (miRNAs) is a liquid biopsy diagnostic approaches. Numerous studies have suggested that some differentially expressed miRNAs may be promising diagnostic markers for PC, but the results have varied among studies. The present study was performed to summarize the diagnostic accuracy of circulating miRNAs, carbohydrate antigen 19-9 (CA19-9), and the combination of miRNAs and CA19-9.Methods: A literature search of online databases including PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI) and WanFang was conducted. Relative data were extracted from eligible included studies, and a meta-analysis was performed.Results: A total of 46 studies involving 4,326 PC patients and 4,277 non-PC controls were included. The pooled sensitivity (SEN), specificity (SPE) and AUC of the circulating miRNAs for differentiating PC patients from non-PC controls were 0.79 (0.77-0.81), 0.77 (0.75-0.79), and 0.85 (0.81-0.87), respectively. For CA19-9, the SEN, SPE and AUC were 0.78 (0.75-0.80), 0.90 (0.85-0.94) and 0.85 (0.82-0.88), respectively. The combination of miRNAs and CA19-9 greatly improved the SEN, SPE and AUC to 0.84 (0.80-0.87), 0.91 (0.89-0.93) and 0.94 (0.92-0.96), respectively. Moreover, circulating miRNAs also yielded an acceptable diagnostic accuracy for early-stage PC with a SEN of 0.79 (0.76-0.82), a SPE of 0.74 (0.68-0.79) and an AUC of 0.81 (0.77-0.84).Conclusions: Circulating miRNAs exhibited satisfactory diagnostic performance for PC and even early-stage PC. The combination of circulating miRNAs and the traditional marker CA19-9 can further improve the diagnostic accuracy, providing a novel strategy for PC diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Meta-analysis of the diagnostic performance of circulating microRNAs for pancreatic cancer

Peng

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…However, insufficient validity was obtained for early-stage PDAC. Regarding these novel genetic biomarkers (ctDNA, CTC and non-coding RNA), some contradictory results have been reported by other researchers [19]. The underlying reasons must be identified and addressed.…”

Section: Blood-based Biomarkers For Early Detection Of Pdacmentioning

confidence: 90%

Trends in biomarker discoveries for the early detection and risk stratification of pancreatic cancer using omics studies

Kobayashi

Honda²

2019

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

“…Liquid biopsy has been used in numerous recent studies to detect tumor-associated biomarkers in different extractable body fluids and is hopeful to monitor response to treatment and disease progression, and to even predict patient outcome (60). Circulating cell-free tumor DNA (ctDNA) is a tumorassociated biomarker released in the bloodstream as a result of tumor cells death and represents the molecular signature of cancer cells.…”

Section: Future Perspectives: Bio-imaging and Bio-markersmentioning

confidence: 99%

Response to Preoperative Therapy in Localized Pancreatic Cancer

2020

View full text Add to dashboard Cite

Evaluation of response to preoperative therapy for patients with pancreatic adenocarcinoma has been historically difficult. Therefore, preoperative regimens have generally been selected on the basis of baseline data such as radiographic stage and serum CA 19-9 level and then typically administered for a pre-specified duration as long as 6 months or more. The decision to proceed with resection following preoperative therapy likewise has rested upon the absence of disease progression rather than evidence for tumor response. This article reviews the basis for the evaluation of therapeutic response after preoperative therapy for pancreatic cancer in the existing scientific literature, and providing updates and new perspectives.

show abstract

Liquid biopsies for management of pancreatic cancer

Cited by 58 publications

References 245 publications

Meta-analysis of the diagnostic performance of circulating microRNAs for pancreatic cancer

Meta-analysis of the diagnostic performance of circulating microRNAs for pancreatic cancer

Trends in biomarker discoveries for the early detection and risk stratification of pancreatic cancer using omics studies

Response to Preoperative Therapy in Localized Pancreatic Cancer

Contact Info

Product

Resources

About